Compare Revvity Inc (RVTY) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs SAP SE — how do they compare? Revvity Inc trades at $154.88 (market cap $16.98B), while SAP SE trades at $215.27 (market cap $238.67B). The key difference: SAP SE is far larger — about 14.1× Revvity Inc's market cap, and SAP SE pays the higher dividend (1.38%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and SAP SE for 118 Days on average.
| RVTY | SAP | |
|---|---|---|
Market Cap | $16.98B | $238.67B |
Volume | 1,456,900 | 2,252,662 |
Sector | Health | Technology |
52-Week High | $157.36 | $280.46 |
52-Week Low | $82.26 | $146.38 |
Typical Hold Time | 12 Days | 118 Days |
Enterprise Value | $19.30B | $237.42B |
Dividend Yield | 0.18% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
SAP trades at $214.26, up 1.97% today, with a bullish technical signal from moving averages and a consensus analyst price target of $253.40. The company reported strong Q1 2026 earnings beat with EPS of $2.01, though Q2 2026 missed expectations. Revenue growth is robust, reaching $36.80B in 2025, with a net income margin of 20.41%. Recent news highlights AI-driven cloud revenue growth and partnerships, supporting positive sentiment.
Outlook remains positive with cloud and AI initiatives driving growth, but risks include competitive pressures and execution challenges. Analysts are predominantly bullish (51.16% buy ratings), seeing upside to the price target. Investors should monitor quarterly earnings consistency and margin trends amid industry volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
